Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.
作者信息
Pollyea Daniel A, Harris Chelsea, Rabe Jennifer L, Hedin Brenna R, De Arras Lesly, Katz Sigrid, Wheeler Emily, Bejar Rafael, Walter Matthew J, Jordan Craig T, Pietras Eric M, Alper Scott
机构信息
Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Department of Biomedical Research, National Jewish Health, Denver, CO.
出版信息
Haematologica. 2019 Sep;104(9):e388-e392. doi: 10.3324/haematol.2018.214155. Epub 2019 Mar 7.
Abstract
摘要
相似文献
1
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.骨髓增生异常综合征相关的剪接体基因突变增强先天性免疫信号传导。
Haematologica. 2019 Sep;104(9):e388-e392. doi: 10.3324/haematol.2018.214155. Epub 2019 Mar 7.
2
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.体细胞剪接体突变在骨髓增生异常综合征中诱导的剪接异常和信使 RNA 产生缺陷。
Nat Commun. 2018 Sep 7;9(1):3649. doi: 10.1038/s41467-018-06063-x.
3
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.剪接体突变对骨髓增生异常综合征中 RNA 剪接的影响：失调的基因/通路和临床关联。
Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.
4
Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.骨髓增生异常综合征中的剪接因子基因突变：对疾病表型和治疗应用的影响。
Adv Biol Regul. 2017 Jan;63:59-70. doi: 10.1016/j.jbior.2016.08.001. Epub 2016 Aug 21.
5
Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.在伴有剪接体突变的骨髓增生异常综合征中，肿瘤抑制性微小RNA表达下调。
Oncotarget. 2016 Mar 1;7(9):9951-63. doi: 10.18632/oncotarget.7127.
6
Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.骨髓增生异常综合征中的剪接因子突变：来自剪接体结构的见解
Trends Genet. 2017 May;33(5):336-348. doi: 10.1016/j.tig.2017.03.001. Epub 2017 Mar 31.
7
A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.一种用于对环形铁粒幼细胞性骨髓增生异常综合征（MDS）患者进行剪接体相关基因测序的两步法，作为一种补充诊断检测方法。
Leuk Res. 2017 May;56:82-87. doi: 10.1016/j.leukres.2017.01.031. Epub 2017 Feb 4.
8
Splicing Factor Mutations in Cancer.癌症中的剪接因子突变
Adv Exp Med Biol. 2016;907:215-28. doi: 10.1007/978-3-319-29073-7_9.
9
Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.不同的剪接特征影响携带不同剪接调节因子突变的骨髓增生异常综合征患者的汇聚通路。
RNA. 2016 Oct;22(10):1535-49. doi: 10.1261/rna.056101.116. Epub 2016 Aug 4.
10
[Deregulated splicing machinery in myelodysplastic syndromes].[骨髓增生异常综合征中失调的剪接机制]
Rinsho Ketsueki. 2012 May;53(5):493-6.
引用本文的文献
1
Association of clonal hematopoiesis of indeterminate potential with cardiometabolic multimorbidity progression and mortality: a prospective study of UK Biobank.具有不确定潜能的克隆性造血与心血管代谢多种疾病进展及死亡率的关联：英国生物银行的一项前瞻性研究
Eur J Med Res. 2025 May 24;30(1):414. doi: 10.1186/s40001-025-02639-8.
2
Low-risk MDS-A spotlight on precision medicine for mutated patients.低风险骨髓增生异常综合征——聚焦于针对突变患者的精准医学
Hemasphere. 2025 Mar 21;9(3):e70103. doi: 10.1002/hem3.70103. eCollection 2025 Mar.
3
Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis.通过转录谱分析和连通性图谱分析鉴定伴有剪接因子突变的骨髓增生异常综合征中的新候选药物
Br J Haematol. 2025 Apr;206(4):1086-1091. doi: 10.1111/bjh.20026. Epub 2025 Feb 23.
4
Clonal hematopoiesis of indeterminate potential, health indicators, and risk of cardiovascular diseases among patients with diabetes: a prospective cohort study.糖尿病患者中具有不确定潜能的克隆性造血、健康指标与心血管疾病风险：一项前瞻性队列研究
Cardiovasc Diabetol. 2025 Feb 13;24(1):72. doi: 10.1186/s12933-025-02626-7.
5
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management.VEXAS综合征：更多关乎炎症还是造血克隆性？关于诊断、治疗策略及移植管理的病例系列研究
Ann Hematol. 2025 Jan;104(1):253-262. doi: 10.1007/s00277-025-06207-2. Epub 2025 Jan 17.
6
Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis Patients.类风湿关节炎患者分离出的中性粒细胞中，免疫调节药物Jusvinza调控的蛋白质组学特征
Biomedicines. 2024 Nov 29;12(12):2740. doi: 10.3390/biomedicines12122740.
7
S-allylmercaptocysteine inhibits TLR4-mediated inflammation through enhanced formation of inhibitory MyD88 splice variant in mammary epithelial cells.S-烯丙基半胱氨酸通过增强乳腺上皮细胞中抑制性 MyD88 剪接变体的形成来抑制 TLR4 介导的炎症。
Sci Rep. 2024 Nov 28;14(1):29627. doi: 10.1038/s41598-024-81304-2.
8
Pathogenesis and inflammaging in myelodysplastic syndrome.骨髓增生异常综合征的发病机制与炎症衰老
Haematologica. 2025 Feb 1;110(2):283-299. doi: 10.3324/haematol.2023.284944.
9
The immunobiology of myelodysplastic neoplasms: a mini-review.骨髓增生异常肿瘤的免疫生物学：一篇小型综述。
Front Immunol. 2024 Sep 16;15:1419807. doi: 10.3389/fimmu.2024.1419807. eCollection 2024.
10
Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow.通过整合骨髓中的炎症、细胞类型组成和免疫特征，鉴定新的骨髓增生异常综合征预后亚组。
Elife. 2024 Sep 5;13:RP97096. doi: 10.7554/eLife.97096.
本文引用的文献
1
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.癌症相关剪接体基因突变的合成致死和趋同生物学效应。
Cancer Cell. 2018 Aug 13;34(2):225-241.e8. doi: 10.1016/j.ccell.2018.07.003.
2
Autoimmune manifestations associated with myelodysplastic syndromes.与骨髓增生异常综合征相关的自身免疫表现。
Ann Hematol. 2018 Nov;97(11):2015-2023. doi: 10.1007/s00277-018-3472-9. Epub 2018 Aug 8.
3
Monocyte function in patients with myelodysplastic syndrome.骨髓增生异常综合征患者的单核细胞功能。
J Leukoc Biol. 2018 Sep;104(3):641-647. doi: 10.1002/JLB.5AB1017-419RR. Epub 2018 Apr 14.
4
Splicing factor gene mutations in hematologic malignancies.血液系统恶性肿瘤中的剪接因子基因突变
Blood. 2017 Mar 9;129(10):1260-1269. doi: 10.1182/blood-2016-10-692400. Epub 2016 Dec 9.
5
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.NLRP3炎性小体作为骨髓增生异常综合征表型的驱动因素发挥作用。
Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.
6
Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.不同的剪接特征影响携带不同剪接调节因子突变的骨髓增生异常综合征患者的汇聚通路。
RNA. 2016 Oct;22(10):1535-49. doi: 10.1261/rna.056101.116. Epub 2016 Aug 4.
7
RNA splicing factors as oncoproteins and tumour suppressors.作为癌蛋白和肿瘤抑制因子的RNA剪接因子
Nat Rev Cancer. 2016 Jul;16(7):413-30. doi: 10.1038/nrc.2016.51. Epub 2016 Jun 10.
8
Regulation of toll-like receptor signaling by the SF3a mRNA splicing complex.SF3a mRNA剪接复合体对Toll样受体信号传导的调控
PLoS Genet. 2015 Feb 6;11(2):e1004932. doi: 10.1371/journal.pgen.1004932. eCollection 2015 Feb.
9
U2AF1 mutations alter splice site recognition in hematological malignancies.U2AF1突变改变血液系统恶性肿瘤中的剪接位点识别。
Genome Res. 2015 Jan;25(1):14-26. doi: 10.1101/gr.181016.114. Epub 2014 Sep 29.
10
Regulation of hematopoietic and leukemic stem cells by the immune system.免疫系统对造血干细胞和白血病干细胞的调控。
Cell Death Differ. 2015 Feb;22(2):187-98. doi: 10.1038/cdd.2014.89. Epub 2014 Jul 4.
Zotero 插件